 | Sophie Dorothea Fosså |
Prominent publications by Sophie Dorothea Fosså
BACKGROUND: Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.
METHODS: This intergroup, open-label, randomised, phase 3 trial recruited patients from hospitals across Europe and Canada. Eligible patients had histologically proven ...
| Also Ranks for: Radical Cystectomy | urothelial carcinoma | 3 trial | patients bladder | treatment chemotherapy |
BACKGROUND: Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases.
METHODS: In this phase 3, double-blind, randomised ALSYMPCA trial, we enrolled patients who had symptomatic ...
| Also Ranks for: Bone Metastases | symptomatic skeletal events | placebo patients | resistant prostate | phase 3 |
PURPOSE: This randomized trial evaluated antitumor activity of and survival asociated with high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) plus granulocyte colony-stimulating factor (HD-MVAC) versus MVAC in patients with advanced transitional-cell carcinoma (TCC).
PATIENTS AND METHODS: A total of 263 patients with metastatic or advanced TCC who had no prior chemotherapy were randomized to HD-MVAC (2-week cycles) or MVAC (4-week ...
| Also Ranks for: Classic Mvac | stimulating factor | granulocyte colony | european organization | doxorubicin cisplatin |
BACKGROUND: The emotional functioning (EF) dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C33) and the Hospital Anxiety and Depression Scale (HADS) evaluate anxiety and depression. We wanted to compare cancer patients' responses to EF with those to HADS, as well as the impact of anxiety and depression on the quality of life (QL) dimensions of the EORTC QLQ C33.
METHOD: A total of 568 cancer patients completed both the ...
| Also Ranks for: European Organization | depression anxiety | life questionnaire | cancer quality | hadsa hadsd |
Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk
[ PUBLICATION ]
BACKGROUND: Given the extended survival of patients diagnosed with cervical cancer, the large number of these women treated with radiotherapy, and the presence in this population of established cancer risk factors such as human papillomavirus (HPV) infection and cigarette smoking, it is important to clarify long-term trends in second cancer risk.
METHODS: Using data from 104,760 one-year survivors of cervical cancer reported to 13 population-based cancer registries in Denmark, Finland, ...
| Also Ranks for: Cervical Cancer | radiotherapy risk | women age | 104760 survivors | united states |
Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population‐based study
[ PUBLICATION ]
OBJECTIVE: To study the concordance between the Gleason scores of needle biopsies and radical prostatectomy (RP) specimens in a population-based registry, to clarify whether the concordance depends on the annual number of RP specimens assessed in the pathology unit, and to identify preoperative clinical factors that predict upgrading from a Gleason score of or=7 in the RP specimen.
PATIENTS AND METHODS: Through the Cancer Registry of Norway, we identified 1116 patients with available ...
| Also Ranks for: Gleason Score | needle biopsies | biopsy rp | prostatectomy specimens | kappa coefficient |
BACKGROUND: Although second primary cancers are a leading cause of death among men with testicular cancer, few studies have quantified risks among long-term survivors.
METHODS: Within 14 population-based tumor registries in Europe and North America (1943-2001), we identified 40,576 1-year survivors of testicular cancer and ascertained data on any new incident solid tumors among these patients. We used Poisson regression analysis to model relative risks (RRs) and excess absolute risks ...
| Also Ranks for: Testicular Cancer | 95 patients | 35 years | malignant mesothelioma | neoplasms survivors |
PURPOSE: To assess morbidity, side effects, and quality of life (QoL) in patients treated for localized prostate cancer with curative aim.
METHODS AND MATERIALS: This descriptive cross-sectional study comprises 154 patients who had undergone definitive radiotherapy (RAD) and 108 patients with radical prostatectomy (PRECT) at the Norwegian Radium Hospital during 1987-1995. At least 1 year after treatment the patients completed several questionnaires assessing quality of life (European ...
| Also Ranks for: Radical Prostatectomy | definitive radiotherapy | qol patients | quality life | localized prostate |
PURPOSE: To test the equivalence of three versus four cycles of bleomycin, etoposide, and cisplatin (BEP) and of the 5-day schedule versus 3 days per cycle in good-prognosis germ cell cancer.
PATIENTS AND METHODS: The study was designed as a 2 x 2 factorial trial. The aim was to rule out a 5% decrease in the 2-year progression-free survival (PFS) rate. The study included the assessment of patient quality of life. A cycle of BEP consisted of etoposide 500 mg/m(2), administered at either ...
| Also Ranks for: Germ Cell | european organization | bleomycin etoposide | day schedule | 3 5 |
BACKGROUND: Several studies have shown the efficacy of endocrine therapy in combination with radiotherapy in high-risk prostate cancer. To assess the effect of radiotherapy, we did an open phase III study comparing endocrine therapy with and without local radiotherapy, followed by castration on progression.
METHODS: This randomised trial included men from 47 centres in Norway, Sweden, and Denmark. Between February, 1996, and December, 2002, 875 patients with locally advanced prostate ...
| Also Ranks for: Endocrine Treatment | prostate cancer | 10 years | cumulative incidence | phase iii |
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations
[ PUBLICATION ]
BACKGROUND: A recent genome-wide association study (GWAS) has identified a single nucleotide polymorphism (SNP) rs11249433 in the 1p11.2 region as a novel genetic risk factor for breast cancer, and this association was stronger in patients with estrogen receptor (ER)+ versus ER- cancer.
RESULTS: We found association between SNP rs11249433 and expression of the NOTCH2 gene located in the 1p11.2 region. Examined in 180 breast tumors, the expression of NOTCH2 was found to be lowest in ...
| Also Ranks for: Breast Cancer | gene expression | snp rs11249433 | estrogen receptor | single nucleotide |
CONTEXT: Some controversy still exists regarding the management of testis cancer following chemotherapy for disseminated disease.
OBJECTIVE: To review the available literature concerning the management of postchemotherapy testis cancer.
EVIDENCE ACQUISITION: A Medline search was conducted to identify original and review articles, as well as guidelines addressing the management of testis cancer following first-line chemotherapy. Keywords included germ cell tumor, testis cancer, ...
| Also Ranks for: Testis Cancer | residual neoplasms | local neoplasm | germ cell | patients masses |
What's known on the subject? And what does the study add? Sexual function is often impaired after radical prostatectomy resulting in reduced sexual activity and sexual bother. The main focus in the literature concerning sexual adverse effects has been on erectile dysfunction and impairment of sexual function rather than the actual sexual bother it causes, although the sexual bother is most important to the individual patient's quality of life. The relation between these measures, and in ...
| Also Ranks for: Radical Prostatectomy | sexual bother | prospective national study | rp patients | postoperative sb |
Sophie Dorothea Fosså: Influence Statistics
| Concept | World rank |
|---|---|
| controls tcss | #1 |
| risk tcss | #1 |
| papers psychometric properties | #1 |
| norwegian–swedish population | #1 |
| consensus conference patients | #1 |
| pn0m0 prostate | #1 |
| unilateral testicular cancer | #1 |
| prognostic relevance her2 | #1 |
| serum interferon levels | #1 |
| 5‐dfurd | #1 |
| cancers testicular cancer | #1 |
| patients fnc | #1 |
| life testicular | #1 |
| nocurtrt | #1 |
| recombinant interferon vinblastine | #1 |
| current work ability | #1 |
| depression tcss | #1 |
| cancer survivors dysfunction | #1 |
| age pof | #1 |
| radiotherapy testicular | #1 |
| period risk | #1 |
| primturb returb | #1 |
| crd42015019747 | #1 |
| perivesical growth | #1 |
| introduction cisplatinbased chemotherapy | #1 |
| 95 tinnitus | #1 |
| 24 months pbs90 | #1 |
| start psa | #1 |
| sunitinib treatment pet | #1 |
| hdct eventfree survival | #1 |
| cancers matched cancers | #1 |
| curtrt mortality | #1 |
| nucg | #1 |
| diagnosed 1980 | #1 |
| igcnu cycles | #1 |
| iep hrqol | #1 |
| neuropsychological functioning baseline | #1 |
| hrcs1 | #1 |
| qolresultsthe | #1 |
| fatherhood cases | #1 |
| cbop bep patients | #1 |
| cancer survivorship europe | #1 |
| arm shoulder morbidity | #1 |
| ldh hcg | #1 |
| hr493 | #1 |
| erectile dysfunction edmed | #1 |
| suggestive linkage evidence | #1 |
| lh levels tcss | #1 |
| hdss genpop | #1 |
Key People For Testicular Cancer
Sophie Dorothea Fosså:Expert Impact
Concepts for whichSophie Dorothea Fossåhas direct influence:Testicular cancer, Germ cell, Prostate cancer, Cancer survivors, Breast cancer, Testicular cancer survivors, Late effects, Radical prostatectomy.
Sophie Dorothea Fosså:KOL impact
Concepts related to the work of other authors for whichfor which Sophie Dorothea Fosså has influence:Prostate cancer, Germ cell, Quality life, Physical activity, Radiation therapy, Bone metastases, Clinical stage.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |